Bevacizumab in Colorectal Cancer: Current Role in Treatment and the Potential of Biosimilars.

about

Bevacizumab in Colorectal Cancer: Current Role in Treatment and the Potential of Biosimilars.

Item

http://www.wikidata.org/entity/Q38643555

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Bevacizumab in Colorectal Canc ...... the Potential of Biosimilars.

@en

type

Item

label

Bevacizumab in Colorectal Canc ...... the Potential of Biosimilars.

@en

prefLabel

Bevacizumab in Colorectal Canc ...... the Potential of Biosimilars.

@en

P1476

Bevacizumab in Colorectal Canc ...... the Potential of Biosimilars.

@en

P2093

Ira A Jacobs

http://www.w3.org/2001/XMLSchema#string

Lee S Rosen

http://www.w3.org/2001/XMLSchema#string

Ronald L Burkes

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial

P2860

A clinician's guide to biosimilars in oncology

Population pharmacokinetics of bevacizumab in cancer patients with external validation

Value of bevacizumab in treatment of colorectal cancer: A meta-analysis

VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4 A resolution and mutational analysis of the interface

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

Development of biosimilars in an era of oncologic drug shortages

Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study.

Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial.

Barriers to the Access and Use of Rituximab in Patients with Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia: A Physician Survey.

The health and economic effects of counterfeit drugs

P2888

s11523-017-0518-1

P31

scholarly article

review article

P356

10.1007/S11523-017-0518-1

http://www.w3.org/2001/XMLSchema#string

P5008

ScienceSource

P577

2017-08-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2017-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1091158025

http://www.w3.org/2001/XMLSchema#string

P698

28801849

http://www.w3.org/2001/XMLSchema#string

P921

P932

5610666

http://www.w3.org/2001/XMLSchema#string